Cambridge, UK; November 8, 2019: Kymab, a clinical-stage biopharmaceutical company developing antibody-based therapeutics, will today present a poster detailing an expanding body of evidence for the activity of the company’s novel immunocytokine, KY1043. The poster will be presented at the Society of Immunotherapy for Cancer (SITC) 34th Annual Meeting being held today at the Gaylord National Hotel and Convention Center, National Harbor, Fort Washington, Maryland, United States.
News
London, UK – Nov. 4, 2019 – Clinical Trials Laboratory Services (CTLS), a leading provider of human blood products and biological specimens to the research community, today announced that it has made several enhancements to the donor experience at its donor center in North West London, UK. CTLS specializes in collecting blood, serum and plasma from consented donors.
Cambridge, UK, 08 November 2019: Horizon Discovery Group plc (LSE: HZD) ("Horizon", “the Company” or “the Group”), a global leader in the application of gene editing and gene modulation technologies, today announces an agreement to divest the Group’s animal research models business unit (“the business unit”) to Envigo RMS LLC (“Envigo”). The divestment forms part of Horizon’s strategy to refocus on high growth areas within its core market and is expected to be completed within 30-45 days, subject to customary closing conditions.
Cambridge, UK, November 07 2019: Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced it has partnered with Thermo Fisher Scientific, the world leader in serving science. The collaboration seeks to advance the application of non-invasive breath sampling to address the challenges of the early detection of disease and the precision medicine delivery of healthcare through the discovery and validation of novel biomarkers.
Cambridge, UK, 7 November 2019: PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today announced the start of the PRECIOUS (Predicting Crohn’s and Colitis Outcomes in the United States) study, which it is jointly funding with the Crohn’s & Colitis Foundation.
Black Belt TX forms a strategic partnership with Praxis Biotech to develop new therapies targeting stress response pathways in cancer.
CAMBRIDGE, UK, NEW YORK, HOUSTON and SOUTH SAN FRANCISCO, 06 November, 2019 — Artios Pharma Limited (Artios), The University of Texas MD Anderson Cancer Center (MD Anderson) and ShangPharma Innovation (ShangPharma) today announce the in-licensing by Artios of a small-molecule ATR inhibitor programme, developed jointly by MD Anderson and ShangPharma.
A new report released today by BioBeat entitled “50 Movers & Shakers in BioBusiness 2019” includes five women from organisations based at Stevenage Bioscience Catalyst (SBC) as well as two Board members. The report highlights the top female talent in the pharma and biotech sectors within the UK.
The report focuses on the impact of individuals in five key areas, namely science, finance, collaboration, patient impact and infrastructure. The SBC-based individuals which spanned the segments are:
Cambridge, UK, 05 November: PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, is delighted to welcome Steven S. Martin to its board.